Changing the Future of Allogenic Engineered T-cell Therapy
Through its groundbreaking ProTcell™ platform, Smart Immune has developed clinical stage T-cell progenitor-based cell and gene therapy to rapidly and fully reset patients’ immune systems to fight cancers and infections.
With ProTcell™, Smart Immune has developed a groundbreaking clinical stage T-cell progenitor-based platform to rapidly and fully reset the patients’ T-cell compartment in order to fight blood cancers and severe infections.
Our ProTcell™ therapy shifts the risk: benefit ratio of allogenic T-cell medicine; significantly reducing adverse events observed in current allogenic practice, thus addressing a large unmet therapeutical need in patients.
The Immune T Cell system is the most efficient weapon for fighting life threatening cancers and infections
What if we could reset it without inducing adverse events ?
Bringing allo HSC curative power to patients in life threatening conditions without inducing adverse events
T Cell Progenitors: a new generation of allogenic T cell medicine enabling a reset of T cell immune system to fight cancers and infections
A rapid efficiency without inducing adverse events to improve significantly life expectancy and quality
Partnership set to develop fully-automated , miniaturized cell-culture bioreactors to produce HSC-derived cell-culture products at scale
Our latest news and updates
Smart Immune Receives IRB Approval For Phase 1/2 Clinical Trial of Proprietary Allogeneic T-cell Product Smart-101 (ProTcellTM) for AML and ALL.
PARIS, France, Oct 13, 2021 – Smart Immune SAS, a T cell medicine company utilizing its proprietary ex-vivo biomimetic “thymus in a dish” technology to develop allogeneic T-cell progenitors Smart101 (ProTcell™) for rapid immune reconstitution, announced today that the institutional review board (IRB) of the Memorial Sloan Kettering Cancer Center (MSK) has approved the commencement of the Company’s phase 1/2 clinical trial. MSK will start enrolling patients in November, 2021.